|
1
|
Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial.
|
JAMA
|
2003
|
3.52
|
|
2
|
A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days.
|
Eur Heart J
|
2007
|
1.71
|
|
3
|
Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial.
|
Circulation
|
2005
|
1.34
|
|
4
|
Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
|
Circulation
|
2004
|
1.07
|
|
5
|
Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial.
|
Circulation
|
2004
|
1.06
|
|
6
|
Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness.
|
Thromb Haemost
|
2006
|
0.83
|
|
7
|
A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib.
|
J Am Coll Cardiol
|
2005
|
0.81
|
|
8
|
A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite.
|
Thromb Haemost
|
2005
|
0.78
|
|
9
|
Expression of CXCR4, VLA-1, LFA-3 and transducer of ERB in G-CSF-mobilised progenitor cells in acute myocardial infarction.
|
Thromb Haemost
|
2010
|
0.77
|